A Selection of Recent Publications by Subject Area

• Endocrine

• Tumour Markers

• Prognosis

• Other Breast Publications

Endocrine

• Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Robertson, J.F.R., Willsher, P.C., Winterbottom, L., Blamey, R.W. Eur. J. Cancer 1999; 35: 214-218
• Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Jacobs, E., Watson, S.A., Michaeli, D., Ellis, I.O., Robertson, J.F.R. Brit. J. Cancer 1999; 80 (3/4): 352-359.
• Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor positive breast cancer. Kenny, F.S., Hui, R., Musgrove, E.A., Gee, J.M.W., Blamey, R.W., Nicholson, R.I., Sutherland, R.L., Robertson, J.F.R. Clin Cancer Research 1999; 5: 2069-2076.
• Immunohistomchemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in breast cancer. Gee, J.M.W., Robertson, J.F.R., Ellis, I.O., Nicholson, R.I., Hurst, H.C. J. Pathol., 1999; 189: 514-520.
• Involvment of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Nicholson, R.I., McClelland, R.A., Robertson, J.F.R., Gee, J.M.W. Endocrine Related Cancer 1999; 6: 1-16.
• Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Robertson, J.F.R., Howell, A., Buzder, A., von Euler, M., Lee, D. Br. Ca. Res. & Treatment 1999; 58: 157-162.
• New calmodulin antagonists inhibit in-vitro growth of human breast cancer cell lines independent of their oestrogen receptor status. Jacobs, E., Bulpitt, P.C.A., Coutts, I.G.C., Robertson, J.F.R. Anticancer Drugs 2000; 11: 63-68.
• Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Kenny, F.S., Pinder, S., Ellis, I.O., Gee, J.M.W., Nicholson, R.I., Bryce, R.P., Robertson, J.F.R. Int. J Cancer 2000; 85: 643-648.
• Preoperative endocrine therapy for breast cancer. Cheung, K.L., Howell, A., Robertson, J.F.R. Endocrine-related Cancer 2000; 7: 131-141
• Selection of primary breast cancer patients for adjuvant endocrine therapy - is oestrogen receptor alone adequate? Cheung, K.L., Nicholson, R.I.N., Blamey, R.W., Robertson, J.F.R. Br. Can. Res. & Treat. 2001; 65: 155-162.
• Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Kenny, F.S., Willsher, P.C., Gee, J.M.W., Nicholson, R.I., Pinder, S.E., Ellis, I.O., Robertson, J.F.R.Br. Can. Res. & Treat. 2001; 65: 135-144.
• Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Gee, J.M.W., Robertson, J.F.R., Ellis, I.O., Nicholson, R.I. Int. J. Cancer 2001; 95: 247-254.
• Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Robertson JFR, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M. Cancer Res. 2001 Sep 15;61(18):6739-46.
• Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JFR, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee.; Investigators Committee Members. Cancer 2001 Nov 1;92(9):2247-58
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Bonneterre J, Thurlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. J Clin Oncol 2000 Nov 15;18(22):3748-57
• Preoperative endocrine therapy for breast cancer. Cheung KL, Howell A, Robertson JFR. Endocrine-Related Cancer 2000; 7:131-41.
• Locally advanced primary breast cancer - Medium term results of a randomised trial of multimodal therapy versus initial hormone therapy. Tan SM, Cheung KL, Willsher PC, Blamey RW, Chan SY, Robertson JFR. Eur J Cancer 2001; 37:2331-8
• Preoperative hormone trials for breast cancer. Cheung KL, Robertson JFR. The Breast 2001; 10:1-5.
• Clinical Therapeutics, Oestrogen Receptor Downregulators: New options in Endocrine Therapy for advanced breast cancer. Robertson JFR. Vol. 24, S. A, 2002.
• Fulvestrant, Formally ICI 182,780, Is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I,. Erikstein B, Webster A, Morris C. Journal of Clinical Oncology. Vol. 20, No. 16, August 15, 2002, pps 3396-3403.
• Fulverstrant, an Estrogen Receoptor Downregulator, Reduces Cell Turnover Index More Effectively than Tamoxifen. Bundred NJ, Anderson E, Nicholson RI, Dowsett M, Dion M, Robertson JFR. Anticancer Research 22: 2317-2320 (2002).
• Case Studies in Endocrine Therapy for Metastatic Breast Cancer. Cheung KL, Robertson JFR. Nova Professional Media. Oxon, UK. 2002
• Fulvestrant. Cheung KL, Robertson JFR. Expert Opinion in Investig. Drugs 2002; 11:30.
• Treatment options for postmenopausal women with tamoxifen-resistant advanced breast cancer. Cheung KL, Robertson JFR. Am J Cancer 2002; 1:293-300.
• Current Role of Endocrine Therapy in the Management of Breast Cancer. Robertson JFR, Breast Cancer 9: 276-281, 2002.

Tumour markers

• The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur. J. Cancer 1999; 35: 47-53.
• Can biological markers improve the management of breast cancer patients? Biomarkers Ad Hoc Group of the UKCCCR Brit. J. Cancer 2000; 82: 1625-1626.
• The role of blood tumor marker measurement (using a biochemical index score and c-erbb2) in directing chemotherapy in metastatic breast cancer. Cheung, K.L., Pinder, S.E., Paish, C., Sadozye A.H., Chan, S.Y., Evans, A.J., Blamey, R.W., Robertson, J.F.R. Int. J. Biol. Markers 2000, 15: 203.
• CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K, Robertson J.F.R. Eur J Cancer. 2001 Feb;37(3):355-63.
• Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cheung KL, Graves CR, Robertson JFR. Cancer Treat Rev. 2000 Apr;26(2):91-102. Review.
• Blood tumour markers in breast cancer - A role in early diagnosis and treatment? Cheung KL. DM thesis, University of Nottingham, 2001.
• The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Cheung KL, Evans AJ, Robertson JFR. Breast Cancer Res Treat. 2001 Jun;67(3):273-8.
• Autoantibodies as circulating cancer markers. Cheung KL, Graves CRL, Robertson JFR. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds), Tumor Markers - Physiology, Pathobiology, Technology and Clinical Applications, AACC Press, Washington, USA 2002; Chapter 10, 123-132.

Prognosis

• C-erbB2 expression predicts response to preoperative chemotherapy in locally advanced breast cancer. Willsher, P.C., Pinder, S., Gee, J.M.W., Ellis, I.O., Chan, S.Y., Nicholson, R.I., Blamey, R.W., Robertson, J.F.R. Anticancer Res 1998; 18: 3695-3698.
• c-erbB2 in serum of patients with breast cancer. Harris, L., Luftner, D., Jaeger, W., Robertson, J.F.R. Int. J. Biological Markers 1999; 14: 8-15.
• c-erbB2 expression in primary breast cancer. Tagliabue, E., Menard, S., Robertson, J.F.R., Harris L. Int. J. Biological Markers 1999; 14: 16-26.
• BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Seery, L.T., Knowlden, J.M., Gee, J.M.W., Robertson, J.F.R., Kenny, F.S., Ellis, I.O., Nicholson, R.I. Int. J. Cancer 1999; 84: 258-262.
• Biological and clinical associations of c-jun activation in human breast cancer. Gee, J.M.W., Barroso, A.F., Ellis, I.O., Robertson, J.F.R., Nicholson, R.I.N. Int. J. Cancer 2000; 89: 177-186.
• Effect of dietary GLA +/- tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. Kenny, F.S., Gee, J.M.W., Nicholson, R.I., Ellis, I.O., Morris, T.M., Watson, S.A., Bryce, R.P.,Robertson, J.F.R. Int. J. of Cancer 2001; 92: 342-347
• E-Cadherin as a Prognostic Indicatior in Primary Breast Cancer. Parker C, Rampaul RS, Pinder SE, Bell J, Wencyk P, Blamey RW, Nicholson RI, Ellis IO, Robertson JFR British Journal of Cancer, 2001; 85:1958-63
• HER-2 in breast cancer - methods of detection, clinical signifcance and future prospects for treatment. Rampaul RS, Pinder SE, Gullick WJ, Robertson JFR, Ellis IO. Critical Reviews in Oncology / Haematology 43 (2002) 231-244

Other Breast Publications

• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. The Lancet 1998; 352: 930-942.
• The effect of Evening Primrose Oil on clinically diagnosed fibroadenomas. Kollias, J., Macmillan, R.D., Sibbering, M., Burrell, H., Robertson, J.F.R. The Breast 2000, 9: 35-36.
• Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. Crombie N, Rampaul RS, Pinder SE, Elston CW, Robertson JFR, Ellis IO. Br J Surg. 2001 Oct;88(10):1324-9.
• Management of advanced breast cancer - a multidiscinplanry approach. Cheung KL, Chan SY, Evans AJ, Winterbottom L, Robertson JFR. The Hong Kong Practitioner Vol. 24, March 2002 114-131
• The Internet: the future source of information for professionals in the field of breast cancer. Robertson JFR. The Breast (2002) 11, 398-401
• LEA 135 expression in primary invasive breast cancer, Rampaul RS, Pinder SE, Robertson JFR and Ellis IO. The Breast (2002) 11, 529-530
• Radio-isotope for occult lesion localisation (ROLL) of the breast does not require extra radiation protection procedures. Rampaul RS, Dudley NJ, Thompson JZ, Burrell H , Evans AJ, Wilson ARM, and Macmillan RD. The Breast (2003)